PAR-25-153 NCI Assay Screening R01 Eligibility Guide
Updated 3 official sources
Quick Answer: PAR-25-153 eligibility in 2026 turns on 6 checks: cancer relevance, assay or screening stage, preliminary feasibility, chemistry or cheminformatics input, clinical trial not allowed status, and a validated output path.
Full answer and how we checked it
PAR-25-153 eligibility in 2026 turns on 6 checks: cancer relevance, assay or screening stage, preliminary feasibility, chemistry or cheminformatics input, clinical trial not allowed status, and a validated output path.
Who this is for: Cancer biology labs, assay-development teams, screening centers, chemical biology groups, immunology teams, medicinal chemistry collaborators, and sponsored-research offices deciding whether a discovery-stage NCI R01 fits.
Data note: This guide uses NIH PAR-25-153 (opens in a new tab), NIH clinical trials policy (opens in a new tab), Grants.gov listing 357014 (opens in a new tab), and Grantsights award-data signals checked on June 2, 2026.
In this guide
- Source Check
- 6 PAR-25-153 Eligibility Stop Checks
- 5 Funding, Timing, and Mechanism Rules
- 5 Route Choices Before Drafting
- What NIH Doesn't Tell You
- 7 Evidence Assets That Make This R01 Stronger
- 7 Source-Backed Search Questions
- 21-Day R01 Routing Plan
- 6 Reviewer-Risk Signals to Fix
- 4 Signals To Check Before You Draft
- 5 Applicant Types and Best Next Move
- 8 Applicant Memo Lines to Include
- 6 Common Route Mistakes
- 9 Review-Ready Proof Points
- Sources
PAR-25-153 is not a general cancer R01. According to NIH PAR-25-153 (opens in a new tab), the route supports discovery research for identifying small molecules that can clarify cancer biology as chemical probes or act as activators or inhibitors of cancer targets.
Some assay projects pair strong biology with an underbuilt screening path. For this route, the application must prove that the assay, screen, and hit-validation logic can survive R01 review.
Use this guide with the live NCI Assay Screening R01 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, Cancer Nanotechnology R01 guide, and the Grantsights grant database.
Source Check
Checked June 2026.
6 official-source checks should happen before a team treats PAR-25-153 as the right R01. NIH listed PAR-25-153 as an NCI R01, clinical trial not allowed, with standard due dates through its September 8, 2026 expiration; the notice has expired, so check PAR-25-153's NIH Guide listing (opens in a new tab) for a reissue. NIH also states that supported discovery stages include primary assay development with pilot screening, primary screen work to identify initial hits, and hit validation with orthogonal assays, cheminformatics, and initial medicinal chemistry inspection.
The route is narrow by stage, not only by topic. A cancer biology project can be strong and still belong in a parent R01 if the assay or screen is not central. A chemistry project can be strong and still miss this route if detailed SAR, ADME, clinical, or late product work dominates.
| Source check | What to verify before writing |
|---|---|
| Trial status | No NIH-defined clinical trial is proposed |
| Cancer relevance | Target, pathway, phenotype, or immune process is tied to cancer |
| Stage fit | Assay development, primary screen, or hit validation is the core work |
| Feasibility | Preliminary assay quality supports the requested stage |
| Validation path | Orthogonal assays, counterscreens, and compound-quality review are named |
| Better route | Parent R01, R21, SBIR/STTR, or later translation route is compared |
The strongest first memo line is simple: this project is a cancer-relevant, non-trial R01 because the assay, screen, or hit-validation stage is ready enough to review.
Get research funding calls by email
About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.
No spam. Unsubscribe anytime.
6 PAR-25-153 Eligibility Stop Checks
6 stop checks decide whether this R01 fits. The project should be cancer-relevant, discovery-stage, non-trial, and built around assay or screening work that can identify useful small-molecule tools or leads.
| Stop check | Strong R01 signal | Red flag |
|---|---|---|
| Cancer relevance | Target or pathway is tied to cancer biology or control | Cancer connection is weak |
| Stage fit | Assay development, screening, or hit validation is central | Late SAR, ADME, or clinical work dominates |
| Feasibility | Preliminary assay quality or screen plan is credible | Primary assay is speculative |
| Chemistry role | Medicinal chemistry or cheminformatics input is present | Hit quality will not be assessed |
| Trial status | No NIH-defined clinical trial | Human intervention assignment is planned |
| Output | Probe, hit set, or validated screen can inform next work | Output is vague |
Don't use this route when the main project is target biology without a screen, or drug development after a hit is already mature.
5 Funding, Timing, and Mechanism Rules
5 public rules should appear in the routing memo. According to NIH, PAR-25-153 is an R01 research project grant and clinical trials are not allowed. PAR-25-153 used NIH standard due dates; the last cycle was June 5, 2026 for new applications and July 5, 2026 for renewals and resubmissions, and the notice expired September 8, 2026; check PAR-25-153's NIH Guide listing (opens in a new tab) for a reissue.
| Rule | Source-backed read |
|---|---|
| Funding number | PAR-25-153 |
| Mechanism | R01 research project grant |
| Clinical trial status | Not allowed |
| Core stages | Assay development, screen implementation, hit validation |
| Last due dates | June 5, 2026 (new) and July 5, 2026 (renewal/resubmission) have passed, and the notice expired September 8, 2026; check NIH for a reissue before planning a submission |
USASpending.gov data shows about $1.14B in FY2024 obligations across 3,308 awards active that year for the connected assistance-listing family in Grantsights. That scale makes the route worth evaluating, but it also means weak fit will not stand out.
5 Route Choices Before Drafting
5 route choices matter because not every cancer chemical biology project belongs here.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-153 R01 | Assay, screen, or hit validation is central | Program fit is strong |
| Parent R01 | Cancer biology is central but screen work is not | Broader route may fit |
| R21 or pilot | Assay feasibility is too early | R01 may be premature |
| SBIR/STTR | Company-led development is central | Small-business path may fit |
| Later translation route | Lead optimization or product development dominates | This route may be too early |
The best first move is to name the project stage. If the application tries to do assay development, full screening, validation, SAR, and in vivo development all at once, it is probably overbuilt.
What NIH Doesn't Tell You
4 hidden readiness questions decide whether PAR-25-153 is worth pursuing.
First, NIH does not make every assay an R01 project. The assay should answer a cancer-relevant problem and support chemical probe or drug discovery logic.
Second, NIH does not let hit validation be an afterthought. Counterscreens, orthogonal assays, selectivity checks, and compound-quality review should be visible.
Third, NIH does not fund detailed SAR or ADME work through this route. Those may be logical next steps, but they are outside the core program fit.
Fourth, NIH does not make clinical trials possible here. The work should remain discovery and preclinical.
According to NIH, PAR-25-153 is Clinical Trial Not Allowed. According to Grants.gov, listing 357014 is the federal listing tied to this route. If the team cannot show controls, signal window, reproducibility, orthogonal validation, and a chemistry triage plan, skip the R01 for now and choose a better route or pilot path.
7 Evidence Assets That Make This R01 Stronger
7 evidence assets make the application easier to defend.
First, define the target or phenotypic system. The cancer relevance should be specific enough for reviewers to judge.
Second, state the stage. NIH names assay development and pilot screening, screen implementation, and hit validation. The application should say which stage it is built around.
Third, show assay quality. Signal window, reproducibility, controls, interference risk, throughput, and validation data matter.
Fourth, include orthogonal validation. A primary screen without a second way to test hits is fragile.
Fifth, include chemistry review. One university in Texas screening small molecules against a fusion oncoprotein model could strengthen its case by adding chemotype triage, PAINS checks, and powder retesting before deeper follow-up.
Sixth, set realistic output. The award should produce an assay, a screen, a validated hit set, or a probe path, not a finished drug.
Seventh, compare next routes. If the project succeeds, the next step may be R01 continuation, SBIR/STTR, NCI translational support, or a chemistry-focused route.
7 Source-Backed Search Questions
7 search questions should be answered clearly. The first is whether PAR-25-153 is cancer-specific. Yes, NCI frames the route around cancer-relevant targets, probes, drugs, and immunomodulators.
The second is whether clinical trials are allowed. They aren't. A human intervention study needs another route.
The third is which project stage fits. NIH names assay development with pilot screening, primary screen implementation, and hit validation.
The fourth is whether the project can cover more than one stage. It can, but NIH expects feasibility and support for the stages proposed.
The fifth is whether hit validation needs chemistry input. The honest read is yes. A screen without chemistry triage can look underbuilt.
The sixth is whether extensive SAR or ADME work fits. NIH lists those as outside this route, so a late development project should look elsewhere.
The seventh is whether a phenotypic screen can fit. It can, but the mechanism and target-deconvolution plan should be credible.
21-Day R01 Routing Plan
21 days is enough to decide whether the team should draft. Days 1 through 3 should confirm PAR-25-153 status, deadline, trial status, cancer relevance, and stage fit.
Days 4 through 7 should build the assay-readiness table: target, readout, controls, signal, throughput, pilot data, and failure thresholds.
Days 8 through 12 should write the screen plan: library, format, counterscreens, false-positive control, and validation assays.
Days 13 through 16 should add chemistry review and hit-prioritization logic.
Days 17 through 21 should compare routes and prepare program-staff questions.
6 Reviewer-Risk Signals to Fix
6 risk signals should be fixed before submission. First, the cancer relevance should not be generic.
Second, the primary assay should not be untested.
Third, the project should not skip orthogonal validation.
Fourth, chemistry input should not be missing if hit triage is central.
Fifth, the application should not promise late-stage development work that the NOFO does not support.
Sixth, the trial status should be clear.
4 Signals To Check Before You Draft
4 signals help you decide whether to draft. Signal 1 is cancer fit: the target, pathway, or phenotype should be specific enough for NCI review.
Signal 2 is stage fit: assay development, screen implementation, and hit validation require different evidence.
Signal 3 is validation fit: orthogonal assays, counterscreens, selectivity checks, and compound-quality review should be visible.
Signal 4 is route fit: compare parent R01, R21, SBIR/STTR, cancer nanotechnology, and academic-industrial translation before drafting.
5 Applicant Types and Best Next Move
5 applicant types commonly ask about PAR-25-153.
| Applicant type | Best next move | Why |
|---|---|---|
| Assay-development lab | Build assay-readiness table | Route may fit |
| Screening center | Define validation and chemistry plan | Hit quality matters |
| Cancer biology PI | Confirm screen is central | Parent R01 may fit better |
| Company-led project | Compare SBIR/STTR | Business route may fit |
| Sponsored-project office | Check trial status and deadline | Technical fit can block |
The best answer is: use PAR-25-153 when the project is cancer-relevant, non-trial, and centered on assay development, screening, or hit validation that can support chemical probe or drug discovery.
If the project can't show assay quality, validation logic, and cancer relevance, don't chase this R01 yet.
8 Applicant Memo Lines to Include
8 memo lines help separate a strong PAR-25-153 project from a broad cancer biology proposal. According to Grantsights data, the connected NCI assistance-listing family recorded about $1.14B in FY2024 obligations, so a weak stage-fit argument is not enough. Line 1 should name the cancer target, pathway, immune process, or phenotype and explain why it matters.
Line 2 should state the stage: primary assay development, initial pilot screen, primary screen implementation, hit validation, or a justified combination.
Line 3 should describe the assay readout, control set, expected signal window, and artifact risks. If the assay is not ready, the memo should say what data will make it ready.
Line 4 should explain how hits will be validated. Orthogonal assays, target-minus controls, cytotoxicity checks, and selectivity assays should not be left for later.
Line 5 should name the chemistry or cheminformatics role. The application should show how the team will avoid poor chemotypes and false-positive compounds.
Line 6 should define the cancer relevance of the output. The final product does not need to be a drug, but it should help chemical probe or drug discovery logic.
Line 7 should state why clinical trials, SAR, and ADME work are outside the project.
Line 8 should define the next route if the screen works. The next step could be a parent R01, a later NCI route, SBIR/STTR, or a chemistry-focused path.
6 Common Route Mistakes
6 mistakes show up often in assay and screening applications. First, teams sometimes pick this route for broad target biology even when the screen is not central. That weakens fit.
Second, teams overpromise the stage. A project can start with assay development, but it should not imply a full discovery pipeline unless preliminary data justify that scope.
Third, teams underbuild hit validation. Reviewers know primary screens can produce large numbers of false positives. The application should show the validation funnel.
Fourth, teams forget medicinal chemistry review. Even early discovery projects need a credible way to judge compound quality.
Fifth, teams blur the line between probe discovery and product development. PAR-25-153 can set up later work, but it isn't a late-stage drug-development route.
Sixth, teams leave route comparison until after writing. It is better to compare parent R01, R21, SBIR/STTR, and NCI translation routes before the first draft.
9 Review-Ready Proof Points
USASpending.gov data shows about $1.14B in FY2024 obligations for the connected NCI assistance-listing family. First, the project should name the target or phenotype. Second, the assay should have controls. Third, the detection method should be matched to the biology. Fourth, the pilot screen should have a realistic compound set. Fifth, the validation plan should include orthogonal assays. Sixth, chemistry review should flag poor compounds early. Seventh, the project should avoid clinical work. Eighth, the output should be a probe, hit set, or validated screen. Ninth, the next route should be clear.
According to NIH, PAR-25-153 covers 3 main discovery stages: assay development with pilot screening, primary screen implementation, and hit validation. That 3-stage frame is the best way to keep the application focused.
The official rule question is simple: what does NIH allow? The judgment question is harder: is the assay mature enough, are the hits likely to be real, and does the team have the chemistry skill to interpret them? A searcher who gets both answers from Grantsights has less reason to bounce back to Google.
A team doing detailed SAR, ADME, or clinical work should leave with a different route in mind. A team with a weak primary assay should leave with a pilot plan. A team with a strong assay but no hit-validation funnel should know what to fix before drafting.
Sources
3 sources anchor this guide: the NIH NCI R01 NOFO, the federal listing, and the Grantsights public database record.
- NIH PAR-25-153 R01 NOFO: grants.nih.gov (opens in a new tab)
- Grants.gov listing 357014: grants.gov (opens in a new tab)
- Grantsights grant database: Search NCI assay and screening routes
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open the NCI R01 record
Check PAR-25-153, clinical-trial-not-allowed status, deadline, and source links.
Compare NCI technology routes
Use when the project is technology development rather than assay, screen, or hit validation.
Compare translation R01
Use when the project is closer to product translation than discovery-stage screening.
Compare NIH mechanisms
Check whether R01, R21, SBIR/STTR, or another NIH route is the better fit.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAR-25-153 fund?
NIH says the R01 supports NCI discovery research for assay development, screening, and hit validation for chemical probes, drugs, or immunomodulators relevant to cancer.
Are clinical trials allowed?
No. PAR-25-153 is clinical trial not allowed.
Which project stages fit?
NIH names primary assay development and pilot screening, screen implementation, and hit validation as supported stages.
Who should skip this route?
Skip it if the target is not cancer-relevant, the project is detailed SAR or ADME work, or the proposal needs a clinical trial.
What is the strongest first check?
Confirm the assay or screen stage, cancer relevance, preliminary feasibility, hit-validation path, and chemistry expertise.
Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-265 Newborn Screening R01 Eligibility
PAR-25-265 newborn screening R01 guide for clinical-trial optional status, R01 versus R21 choice, system fit, therapy evidence, and budget checks.
PAR-25-338 academic industrial R01 eligibility Guide
PAR 25 338 academic industrial guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-106 Cancer Nanotechnology R01 Eligibility Guide
NIH PAR-25-106 guide: NCI cancer nanotechnology R01 eligibility, clinical-trial-not-allowed fit, nanoscale criteria, and review checks.
Chemical Screening Optimization X01 Eligibility Guide
Chemical Screening and Optimization Facility X01 eligibility guide: NICHD services, no-award access, 12-month plans, and fit checks.
PAR-24-280 clinical observational R01 eligibility Guide
PAR 24 280 clinical guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-317 family health R01 eligibility Guide
PAR 25 317 family health guide: 7 checks for eligibility, source status, budget, evidence, route fit, review criteria, and next steps in 2026.